Research Analysts Issue Forecasts for NTLA FY2025 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Intellia Therapeutics in a research note issued to investors on Monday, March 17th. Cantor Fitzgerald analyst R. Bienkowski expects that the company will post earnings of ($4.34) per share for the year. The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share.

NTLA has been the subject of several other research reports. The Goldman Sachs Group reaffirmed a “sell” rating and issued a $9.00 price objective on shares of Intellia Therapeutics in a report on Friday, February 28th. Morgan Stanley downgraded shares of Intellia Therapeutics from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $56.00 to $11.00 in a report on Monday, January 27th. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research report on Monday, March 3rd. Oppenheimer dropped their price target on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a research report on Monday, January 13th. Finally, HC Wainwright initiated coverage on shares of Intellia Therapeutics in a research report on Wednesday, March 5th. They issued a “buy” rating and a $30.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $37.56.

Intellia Therapeutics Stock Up 1.2 %

NTLA stock opened at $9.30 on Wednesday. The company has a market capitalization of $962.71 million, a P/E ratio of -1.71 and a beta of 1.97. The company has a 50-day simple moving average of $10.18 and a 200 day simple moving average of $14.37. Intellia Therapeutics has a fifty-two week low of $8.30 and a fifty-two week high of $28.54.

Insider Activity

In other news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the transaction, the chief executive officer now owns 941,115 shares in the company, valued at $11,462,780.70. This represents a 2.77 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 29,000 shares of company stock worth $352,551 in the last 90 days. Company insiders own 3.20% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Large investors have recently made changes to their positions in the company. State Street Corp grew its stake in shares of Intellia Therapeutics by 17.9% in the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company’s stock valued at $105,700,000 after buying an additional 780,754 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in Intellia Therapeutics by 125.2% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 120,997 shares of the company’s stock worth $1,411,000 after purchasing an additional 67,276 shares during the period. Patient Square Capital LP bought a new stake in Intellia Therapeutics during the third quarter worth approximately $2,642,000. Charles Schwab Investment Management Inc. boosted its position in Intellia Therapeutics by 4.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 827,545 shares of the company’s stock worth $17,006,000 after purchasing an additional 37,714 shares during the period. Finally, Avanza Fonder AB bought a new stake in Intellia Therapeutics during the fourth quarter worth approximately $421,000. Institutional investors own 88.77% of the company’s stock.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.